J 2022

Insights into Antimalarial Activity of N-Phenyl-Substituted Cinnamanilides

KOS, Jiří, Gilles DEGOTTE, Dominika PINDJAKOVA, Tomáš STRHÁRSKY, Timotej JANKECH et. al.

Basic information

Original name

Insights into Antimalarial Activity of N-Phenyl-Substituted Cinnamanilides

Authors

KOS, Jiří (203 Czech Republic, guarantor, belonging to the institution), Gilles DEGOTTE, Dominika PINDJAKOVA, Tomáš STRHÁRSKY (703 Slovakia, belonging to the institution), Timotej JANKECH, Tomáš GONĚC (203 Czech Republic, belonging to the institution), Pierre FRANCOTTE, Michel FREDERICH (203 Czech Republic) and Josef JAMPILEK (203 Czech Republic)

Edition

Molecules, Basel, MDPI, 2022, 1420-3049

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 4.600

RIV identification code

RIV/00216224:14110/22:00127693

Organization unit

Faculty of Medicine

UT WoS

000887320300001

Keywords in English

cinnamanilides; antiplasmodial activity; Plasmodium; structure-activity relationships

Tags

International impact, Reviewed
Změněno: 27/1/2023 10:52, Mgr. Tereza Miškechová

Abstract

V originále

Due to the urgent need of innovation in the antimalarial therapeutic arsenal, a series of thirty-seven ring-substituted N-arylcinnamanilides prepared by microwave-assisted synthesis were subjected to primary screening against the chloroquine-sensitive strain of P. falciparum 3D7/MRA-102. The lipophilicity of all compounds was experimentally determined as the logarithm of the capacity factor k, and these data were subsequently used in the discussion of structure-activity relationships. Among the screened compounds, fourteen derivatives exhibited IC50 from 0.58 to 31 µM, whereas (2E)-N-(4-bromo-2-chlorophenyl)-3-phenylprop-2-enamide (24) was the most effective agent (IC50 = 0.58 µM). In addition, (2E)-N-[2,6-dibromo-4-(trifluoromethyl)- phenyl]-3-phenylprop-2-enamide (36), (2E)-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-phenylprop- 2-enamide (18), (2E)-N-(2-bromo-5-fluorophenyl)-3-phenylprop-2-enamide (23), and (2E)-3-phenyl-N-(3,4,5-trichlorophenyl)prop-2-enamide (33) demonstrated efficacy in the IC50 range from 2.0 to 4.3 µM, comparable to the clinically used standard chloroquine. The results of a cell viability screening performed using THP1-Blue™ NF-κB cells showed that none of these highly active compounds displayed any significant cytotoxic effect up to 20 μM, which makes them promising Plasmodium selective substances for further investigations.